-

Toragen, Inc. Announces Appointment of Chief Scientific Officer

Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”)

SAN DIEGO--(BUSINESS WIRE)--Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), announced today that it has promoted Rick Lumpkin, PhD to the role of Chief Scientific Officer.

Dr. Lumpkin joined Toragen in late 2018 as a consultant and became a fulltime employee in mid-2022. Sandra Coufal, MD, Toragen’s CEO said, “We are thrilled to have Rick as our Chief Scientific Officer as he brings over 30 years of significant experience in early-stage biotechnology companies and synthetic chemistry. Rick has already made important discoveries at Toragen and has directed the foundational science to swiftly proceed to the clinic.”

Prior to Toragen, Dr. Lumpkin served as a founding employee at Global Blood Therapeutics, Portola Pharmaceuticals and Millennium Pharmaceuticals. Additionally, Dr. Lumpkin brings experience from COR Therapeutics, Ribogene, Amylin and Corvas International, Inc.

About Toragen

Toragen, Inc. is targeting the root cause of virally induced cancers. https://toragen.com.

Contacts

Toragen, Inc.
Cheryl Collett
CFO
ccollett@toragen.com

Industry:

Toragen, Inc.

Release Versions
English

Contacts

Toragen, Inc.
Cheryl Collett
CFO
ccollett@toragen.com

More News From Toragen, Inc.

Toragen, Inc., Receives Grant to Conduct Studies to Explore Application of TGN-S15 for Premalignant Lesions at Earliest Stages

SAN DIEGO--(BUSINESS WIRE)--Toragen, Inc., an oncology biopharmaceutical company focused on the development of TGN-S15, their oral, small molecule drug candidate, today announced the receipt of a grant from the Gates Foundation. The grant will support research that includes both in vitro and in vivo studies, with the goal of further validating the application of TGN-S15 as a first-in-class small molecule drug candidate that actually inhibits the E5 viral protein produced by HPV once this virus...

Toragen, Inc. Announces $12 Million Convertible Note Financing and Expansion of Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Toragen, Inc., a clinical-stage biotechnology company developing a first-in-class, oral small molecule HPV E5 protein inhibitor targeting cancers caused by the human papillomavirus (“HPV”), today announced the successful completion of a $12 million convertible note financing. The financing was led by Steven Lebow, who will join Toragen’s Board of Directors along with his designee, Dr. Scott Rasgon. GenHenn Capital also participated with a significant investment and w...

Toragen, Inc. Provides Update on Phase 1 Clinical Trial of TGN-S11 as Monotherapy and in Combination with Keytruda® in Patients with Stage 4 HPV-Associated Cancers

SAN DIEGO--(BUSINESS WIRE)--Today, Toragen, Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from its Phase 1 trial of TGN-S11, a small molecule inhibitor of the human papillomavirus (HPV) E5 oncogene protein, in patients with cancers associated with HPV. This Phase 1 trial was an open-label, non-randomized study in multiple cohorts of patients with relapsed, resistant,...
Back to Newsroom